HDAC7 and acute lymphoblastic leukemia: As a proof-of-concept, after exposing SEM-K2-shHDAC7 cells to MI-538 (+ chidamide) therapy, cells were subjected to in vitro assays to verify whether the blockade of leukemogenic properties in t(4;11) pro-B-ALL cells depends on the induction of HDAC7.